Clinical Features at Baseline Cannot Predict Symptom Response to Placebo in Patients With Eosinophilic Esophagitis

Ikuo Hirano, Evan S. Dellon, Margaret H. Collins, James Williams, Lan Lan, David A Katzka

Research output: Contribution to journalShort survey

Abstract

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease characterized by ≥15 eosinophils per high-power field (eos/hpf) and esophageal dysfunction.1 One confounder in the assessment of drug efficacy in clinical trials for EoE2 and other gastrointestinal diseases3,4 has been the symptomatic response to placebo. In placebo-controlled, randomized trials of EoE therapies, placebo response rates as high as 78% have been reported.2 To mitigate placebo effect, a phase 2, randomized, double-blind, placebo-controlled trial of budesonide oral suspension (BOS) was designed with a single-blind, placebo run-in to attempt to screen out placebo responders before randomization.5 The aim of this post hoc analysis was to identify clinical factors associated with a symptom response during the placebo run-in.

Original languageEnglish (US)
Pages (from-to)2126-2128.e1
JournalClinical Gastroenterology and Hepatology
Volume17
Issue number10
DOIs
StatePublished - Sep 1 2019

Fingerprint

Eosinophilic Esophagitis
Placebos
Budesonide
Placebo Effect
Immune System Diseases
Eosinophils
Suspensions
Randomized Controlled Trials
Clinical Trials

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Clinical Features at Baseline Cannot Predict Symptom Response to Placebo in Patients With Eosinophilic Esophagitis. / Hirano, Ikuo; Dellon, Evan S.; Collins, Margaret H.; Williams, James; Lan, Lan; Katzka, David A.

In: Clinical Gastroenterology and Hepatology, Vol. 17, No. 10, 01.09.2019, p. 2126-2128.e1.

Research output: Contribution to journalShort survey

Hirano, Ikuo ; Dellon, Evan S. ; Collins, Margaret H. ; Williams, James ; Lan, Lan ; Katzka, David A. / Clinical Features at Baseline Cannot Predict Symptom Response to Placebo in Patients With Eosinophilic Esophagitis. In: Clinical Gastroenterology and Hepatology. 2019 ; Vol. 17, No. 10. pp. 2126-2128.e1.
@article{6c0b392741a5435c8103374a6c61a087,
title = "Clinical Features at Baseline Cannot Predict Symptom Response to Placebo in Patients With Eosinophilic Esophagitis",
abstract = "Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease characterized by ≥15 eosinophils per high-power field (eos/hpf) and esophageal dysfunction.1 One confounder in the assessment of drug efficacy in clinical trials for EoE2 and other gastrointestinal diseases3,4 has been the symptomatic response to placebo. In placebo-controlled, randomized trials of EoE therapies, placebo response rates as high as 78{\%} have been reported.2 To mitigate placebo effect, a phase 2, randomized, double-blind, placebo-controlled trial of budesonide oral suspension (BOS) was designed with a single-blind, placebo run-in to attempt to screen out placebo responders before randomization.5 The aim of this post hoc analysis was to identify clinical factors associated with a symptom response during the placebo run-in.",
author = "Ikuo Hirano and Dellon, {Evan S.} and Collins, {Margaret H.} and James Williams and Lan Lan and Katzka, {David A}",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.cgh.2018.11.045",
language = "English (US)",
volume = "17",
pages = "2126--2128.e1",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Clinical Features at Baseline Cannot Predict Symptom Response to Placebo in Patients With Eosinophilic Esophagitis

AU - Hirano, Ikuo

AU - Dellon, Evan S.

AU - Collins, Margaret H.

AU - Williams, James

AU - Lan, Lan

AU - Katzka, David A

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease characterized by ≥15 eosinophils per high-power field (eos/hpf) and esophageal dysfunction.1 One confounder in the assessment of drug efficacy in clinical trials for EoE2 and other gastrointestinal diseases3,4 has been the symptomatic response to placebo. In placebo-controlled, randomized trials of EoE therapies, placebo response rates as high as 78% have been reported.2 To mitigate placebo effect, a phase 2, randomized, double-blind, placebo-controlled trial of budesonide oral suspension (BOS) was designed with a single-blind, placebo run-in to attempt to screen out placebo responders before randomization.5 The aim of this post hoc analysis was to identify clinical factors associated with a symptom response during the placebo run-in.

AB - Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease characterized by ≥15 eosinophils per high-power field (eos/hpf) and esophageal dysfunction.1 One confounder in the assessment of drug efficacy in clinical trials for EoE2 and other gastrointestinal diseases3,4 has been the symptomatic response to placebo. In placebo-controlled, randomized trials of EoE therapies, placebo response rates as high as 78% have been reported.2 To mitigate placebo effect, a phase 2, randomized, double-blind, placebo-controlled trial of budesonide oral suspension (BOS) was designed with a single-blind, placebo run-in to attempt to screen out placebo responders before randomization.5 The aim of this post hoc analysis was to identify clinical factors associated with a symptom response during the placebo run-in.

UR - http://www.scopus.com/inward/record.url?scp=85070863105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070863105&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2018.11.045

DO - 10.1016/j.cgh.2018.11.045

M3 - Short survey

C2 - 30502508

AN - SCOPUS:85070863105

VL - 17

SP - 2126-2128.e1

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 10

ER -